Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma

Oncogene

Volumn 24, Issue 3, 2005, Pages 419-430

  Nasr, Rihab ^a   El Sabban, Marwan E ^a   Karam, José Antonio ^a   Dbaibo, Ghassan ^a   Kfoury, Youmna ^a   Arnulf, Bertrand ^b   Lepelletier, Yves ^b   Bex, Françoise ^c   De Thé, Hugues ^d   Hermine, Olivier ^b   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d CNRS   (France)

Author keywords

HTLV I; Leukemia; Lymphoma; Proteasome inhibitors; PS 341; Treatment

Indexed keywords

BORTEZOMIB; CERAMIDE; DOXORUBICIN; ETOPOSIDE; I KAPPA B; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53; TAX PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN STABILITY; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; HUMANS; JURKAT CELLS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOMA, T-CELL; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 19944434172     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1208212     Document Type: Article

References (51)

1. Adams J. (2003). Cancer Treat. Rev., 29, 3-9.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ. (1999). Cancer Res., 59, 2615-2622.
3. Alam A, Cohen LY, Aouad S and Sekaly RP. (1999). J. Exp. Med., 190, 1879-1890.
4. An WG, Hwang SG, Trepel JB and Blagosklonny MV. (2000). Leukemia, 14, 1276-1283.
5. Baeurle PA and Baltimore D. (1996). Cell, 87, 13-20.
6. Bangham CR. (2000). Curr. Opin. Immunol., 12, 397-402.
7. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O and de The H. (1999). Blood, 93, 278-283.
8. Bazarbachi A and Hermine O. (1996). J. Acquir. Immune Def. Syndrome Hum. Retrovirol., 13, S186-S190.
9. Bazarbachi A and Hermine O. (2001). Virus Res., 78, 79-92.
10. Bielawska A, Perry DK and Hannun YA. (2001). Anal. Biochem., 298, 141-150.
11. Bligh EG and Dyer WJ. (1959). Can. J. Biochem. Phys., 37, 911-917.
12. Cereseto A, Diella F, Mulloy JC, Cara A, Michieli P, Grassmann R, Franchini G and Klotman ME. (1996). Blood, 88, 1551-1560.
13. Dbaibo GS, Pushkareva MY, Jayadev S, Schwarz JK, Horowitz JM, Obeid LM and Hannun YA. (1995). Proc. Natl. Acad. Sci. USA, 92, 1347-1351.
14. De La Fuente C, Santiago F, Chong SY, Deng L, Mayhood T, Fu P, Stein D, Denny T, Coffman F, Azimi N, Mahieux R and Kashanchi F. (2000). J. Virol., 74, 7270-7283.
15. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H and Bazarbachi A. (2000). Blood, 96, 2849-2855.
16. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE and Beran M. (2003). Haematologica, 88, 853-863.
17. Ghosh S and Karin M. (2002). Cell, 109, S81-S96.
18. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S and Levine A. (1995). N. Engl. J. Med., 332, 1744-1748.
19. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F and Diebold J. (1998). Blood, 92, 76-82.
20. Hannun YA. (1996). Science, 274, 1855-1859.
21. Hermine O, Allard I, Levy V, Arnulf B, Gessain A and Bazarbachi A. (2002). Hematol. J., 3, 276-282.
22. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F and Bazarbachi A. (1995). N. Engl. J. Med., 332, 1749-1751.
23. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N and Anderson KC. (2003). Blood, 101, 1530-1534.
24. Huang Y, Johnson KR, Norris JS and Fan W. (2000). Cancer Res., 60, 4426-4432.
25. Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, Tsukamoto K, Noguchi Y, Isomoto H, Takeshima F, Murase K, Kamihira S, Tomonaga M and Kohno S. (1999). Int. J. Cancer, 82, 599-604.
26. Jentsch S and Schlenker S. (1995). Cell, 82, 881-884.
27. Kanno T, Brown K, Franzoso G and Siebenlist U. (1994). Mol. Cell. Biol., 14, 6443-6451.
28. Kawakami A, Nakashima T, Sakai H, Urayama S, Yamasaki S, Hida A, Tsuboi M, Nakamura H, Ida H, Migita K, Kawabe Y and Eguchi K. (1999). Blood, 94, 3847-3854.
29. Kawata S, Ariumi Y and Shimotohno K. (2003). J. Virol., 77, 7291-7299.
30. Kitajima I., Shinohara T, Bilakovics J, Brow DA, Xu X and Nerenberg M. (1992). Science, 258, 1792-1795.
31. Lau A, Nightingale S, Taylor GP, Gant TW and Cann AJ. (1998). Blood, 91, 2467-2474.
32. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM and Perez-Soler R. (2003). Clin. Cancer Res., 9, 1145-1154.
33. Lomas M, Hanon E, Tanaka Y, Bangham CR and Gould KG. (2002). J. Gen. Virol., 83, 641-650.
34. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA and Berenson JR. (2003). Clin. Cancer Res., 9, 1136-1144.
35. Mahieux R, Pise-Masison CA, Lambert PF, Nicot C, De Marchis L, Gessain A, Green P, Hall W and Brady JN. (2000). J. Virol., 74, 6866-6874.
36. Mitra-Kaushik S, Harding JC, Hess J and Ratner L. (2004). Blood, 104, 802-809.
37. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, Staudt L, De The H and Bazarbachi A. (2003). Blood, 101, 4576-4582.
38. Obeid LM, Linardic CM, Karolak LA and Hannun YA. (1993). Science, 259, 1769-1771.
39. Olson NE, Graves JD, Shu GL, Ryan EJ and Clark EA. (2003). J. Immunol., 170, 6065-6072.
40. Pham LV, Tamayo AT, Yoshimura LC, Lo P and Ford RJ. (2003). J. Immunol., 171, 88-95.
41. Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C and Brady JN. (2000). Mol. Cell. Biol., 20, 3377-3386.
42. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S and Matsuoka M. (2004). Leukemia, 18, 1357-1363.
43. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ and Murphy WJ. (2003). Blood, 102, 3-10.
44. Sun SC, Elwood J, Beraud C and Greene WC. (1994). Mol. Cell. Biol., 14, 7377-7384.
45. Sun SC, Harhaj EW, Xiao G and Good L. (2000). Res. Hum. Retroviruses, 16, 1591-1596.
46. Tamiya S, Etoh K, Suzushima H, Takatsuki K and Matsuoka M. (1998). Blood, 91, 3935-3942.
47. Tan C and Waldmann TA. (2002). Cancer Res., 62, 1083-1086.
48. Wattel E, Vartanian JP, Pannetier C and Wain-Hobson S. (1995). J. Virol., 69, 2863-2868.
49. Yamaoka S, Inoue H, Sakurai M, Sugiyama T, Hazama M, Yamada T and Hatanaka M. (1996). EMBO J., 15, 873-887.
50. Yoshida M. (2001). Annu. Rev. Immunol., 19, 475-496.
51. Zar JH. (1999). Biostatistical Analysis 4th edn. Prentice Hall: Englewood Cliffs, NJ.